cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Medicine & Pharmacology
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 25 Documents
 1   2   3 
Search results for , issue "Vol. 13 No. 4 (2025)" : 25 Documents clear
Formulation and evaluation of a bifonazole-loaded chitosan-honey invasomal hydrogel for enhanced topical antifungal activity Patil, Shivaji; Bhargav, Sushil
Journal of Applied Pharmaceutical Research Vol. 13 No. 4 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i4.1301

Abstract

Background: To develop a novel bifonazole-loaded chitosan-honey invasomal hydrogel to improve the drug's topical antifungal efficacy. In this formulation, invasomal vesicles, composed of phospholipids, ethanol, and terpenes, were utilized to enhance the penetration of bifonazole through the skin. Methodology: These invasomal carriers were incorporated into a chitosan-based hydrogel matrix, which provided structural stability and bioadhesive properties, allowing for better retention on the skin. Additionally, natural honey, known for its antibacterial and wound-healing properties, was included to enhance the therapeutic benefits of the hydrogel. Results & Discussion: Invasomes were prepared using soya phosphatidylcholine, ethanol (30% v/v), and d-limonene (0.5%) and then incorporated into a chitosan-honey gel matrix. Among the six formulations (IF1–IF6), IF5 showed optimal results, with 93.32% drug release over 12 hours, a viscosity of 6545 ± 26 cps, a pH of 6.85, and antifungal inhibition zones of 17 mm (Candida albicans) and 11 mm (A. flavus). The formulation was characterized in terms of its physical properties, including viscosity, gel strength, and spreadability, and evaluated for its drug entrapment efficiency, in vitro drug release profile, and ex vivo skin permeation. This study demonstrates a synergistic system enhancing skin permeation, drug retention, and antifungal efficacy. Conclusion: This formulation represents a promising alternative for the effective and patient-friendly treatment of superficial fungal infections, offering improved drug delivery, enhanced therapeutic efficacy, and a reduced dosing frequency.
In silico assessment of flavonoids from Matricaria chamomilla for anti-psoriatic potential via molecular docking and ADME/T profiling V. V. Rajesham; Pentu, Narendra; Kumar, Pasupuleti Kishore; T. Rama Rao; Morsu, Ashok
Journal of Applied Pharmaceutical Research Vol. 13 No. 4 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i4.1309

Abstract

Background: Computational tools are advancing in the drug discovery process to assess the safety profiles of new compounds with reduced investment. Herbal remedies exhibit a diverse range of active compounds that can alleviate various disease conditions with fewer side effects. Method: This study investigates the molecular docking of phytochemicals from Matricaria Chamomilla against inflammation-induced skin disorders, such as psoriasis. Using AutoDock Vina and MGL Tools, key compounds were evaluated for binding affinity with target proteins. ADMET analysis, as assessed by pkCSM and SWISSADME, to predict the Lipinski’s Rule of Five. Redocking was implemented to confirm the binding affinity of the docked position. Results: This molecular docking of phenolic compounds and flavonoids, including quercetin, apigenin, rutin, luteolin, and various glycosylated derivatives—from Matricaria Chamomilla against cellular proteins implicated in psoriasis (PDE-4, p38MAPK, IL-23, BTK, JAK-3, TNF-α, IL-17A, and IL-6). Using Autodock Vina and MGL Tools, rutin and quercetin demonstrated favourable binding affinities. At the same time, luteolin-7-glycoside exhibited the highest docking scores (e.g., -10.8 kcal/mol for PDE-4, -9.7 kcal/mol for JAK-3, and -9.1 kcal/mol for TNF-α) compared to the standard. Results highlight the potential of chamomile phytochemicals as safe, orally effective agents for managing inflammatory skin conditions. Redocking confirms the RMSD values are within the limits of < 2 A0. Conclusion: The data suggest that chamomile flavonoids could be safe and beneficial for treating inflammatory diseases and psoriasis. Although enzymatic and cell-based assays, along with further preclinical evaluations, are essential for advancing research in disease modification, formulation strategies play a role in improving drug characteristics
Design, optimization, and antimicrobial assessment of Callicarpa longifolia-derived nanoparticles using quality by design (QbD) approach Md. Shakeel Alam; Srivastava, Nidhi
Journal of Applied Pharmaceutical Research Vol. 13 No. 4 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i4.1322

Abstract

Background: The purpose of this study is to focus on the design, optimization, and antimicrobial evaluation of ethanolic leaf extracts of Callicarpa longifolia-derived nanoparticles using the Quality by Design (QbD) technique. Methodology: Critical formulation parameters were optimized using a Box-Behnken Design. The optimized nanoparticles are characterized using Dynamic Light Scattering (DLS), Zeta Potential analysis, and Scanning Electron Microscopy (SEM), confirming their nanoscale size. Stability studies were conducted under various ICH recommendations. The antimicrobial activity of the isolated fraction extract and isolated fraction extract nanoparticles was assessed against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria using the agar well diffusion method. Results and Discussion: By BBD, the optimized herbal nanoparticles have a particle size of 281.00 nm and an entrapment efficiency 88%. After characterization, the results of the optimized nanoparticles' particle size (349.3 nm), zeta potentials (-23.7 mV), % EE (86.25%), and spherical shape are confirmed by SEM. The % cumulative drug release of optimized nanoparticles is 86.12±0.79. Kinetic release model regression values of the optimized nanoparticles' R² values in different model kinetic releases are zero order (0.929), first order (0.971), Higuchi kinetic release (0.994), Korsmeyer kinetic release (0.994), and Hixon Crowell (0.978). Results revealed that the nanoparticle formulation exhibited significant antimicrobial efficacy. Conclusion: All things considered, the study shows how the QbD methodology may be successfully applied to create a stable and efficient nanoparticle system made from an isolated extract of C. longifolia, which has encouraging potential as a substitute antibacterial agent.
Investigation of potential efficacy of nanospanlastic vesicular drug delivery system for targeting the brain: formulation, characterization, and in-vivo studies Patel, Ashwini; Pandey, Prachi
Journal of Applied Pharmaceutical Research Vol. 13 No. 4 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i4.1340

Abstract

Background: Edaravone, a potent antioxidant, has limited brain bioavailability due to poor solubility and restricted permeability across the blood-brain barrier (BBB). Intranasal delivery offers a promising alternative for brain targeting by bypassing the BBB. Objective: To develop and evaluate a nanospanlastic-based in-situ nasal gel formulation of edaravone for enhanced brain delivery. Methodology: A Quality by Design (QbD) approach was employed to identify and optimize critical formulation variables using Plackett-Burman and Central Composite Design. The optimized nanospanlastics were incorporated into a gellan gum-based ion-activated in-situ nasal gel and characterized through in vitro, ex vivo, and in vivo studies. Results and Discussion: The optimized formulation exhibited a particle size of 213.4 nm, a drug entrapment efficiency of 67.59%, and rapid gelation upon contact with nasal fluid. In vitro diffusion showed over 80% drug release within 30 minutes, while ex vivo studies confirmed improved permeation (flux: 7.8067 µg/cm²/hr). Histopathology revealed no nasal mucosal irritation. Pharmacokinetic studies in rats demonstrated significantly enhanced brain and plasma exposure compared to the marketed edaravone injection, with higher Cmax (78.73 ng/mL), Tmax (121.2 min), and AUC. Conclusion: The developed nanospanlastic-based nasal gel offers a non-invasive, effective strategy for brain delivery of edaravone, with potential to improve therapeutic outcomes in neurological disorders.
A QbD-based stability-indicating RP-HPLC method for larotrectinib: degradation kinetics and integrated white, green, and blue analytical assessment P. N. S, Syamala; Adikay, Sreedevi
Journal of Applied Pharmaceutical Research Vol. 13 No. 4 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i4.1436

Abstract

Background: Larotrectinib, a selective TRK inhibitor, received FDA approval on April 10, 2025, for treating solid tumors with NTRK gene fusions. Despite its therapeutic significance, no RP-HPLC method using a Quality-by-Design (QbD) framework has been reported. This study aimed to develop and validate a QbD-based RP-HPLC method for larotrectinib estimation. Methodology: Critical Analytical Parameters (CAPs) were identified using a Plackett–Burman Design and optimized via a Central Composite Design (CCD). Separation was achieved on a Sunfire C18 column (250 × 4.6 mm, 5 µm) with a mobile phase of 0.1% OPA and acetonitrile (70:30, v/v), flow rate 1.0 mL/min, injection volume 10 µL, and detection at 262 nm. Optimized conditions from the Method Operable Design Region (MODR) gave a desirability value of 1. Results and Discussion: The method achieved sharp separation with a retention time of 2.2 min in a 5-minute runtime. Validation per ICH Q2(R1) confirmed linearity (12.5–75 µg/mL, R² = 0.9998), intra- and inter-day precision (%RSD < 2%), mean recovery of 99.29%, and sensitivity with DL 0.30 µg/mL and QL 0.92 µg/mL. Forced degradation studies revealed zero-order kinetics under 0.1 N HCl, 0.5 N NaOH, and thermal stress, and first-order kinetics under 0.5 N HCl, 0.1N NaOH, 3% and 5% H₂O₂, and water. Greenness, blueness, whiteness, and sustainability were assessed using AMGS, AGREE, ComplexMoGAPI, BAGI, RGB, and EVG tools, yielding favourable outcomes. Conclusion: The developed QbD-based RP-HPLC method is robust, validated, and stability-indicating, suitable for quality control, regulatory submissions, and bioanalysis of larotrectinib.

Page 3 of 3 | Total Record : 25

 1   2   3 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol 7 No 3 (2019) Vol. 7 No. 3 (2019) Vol 7 No 2 (2019) Vol. 7 No. 2 (2019) Vol 7 No 1 (2019) Vol. 7 No. 1 (2019) Vol 6 No 4 (2018) Vol. 6 No. 4 (2018) Vol 6 No 3 (2018) Vol. 6 No. 3 (2018) Vol 6 No 2 (2018) Vol. 6 No. 2 (2018) Vol 6 No 1 (2018) Vol. 6 No. 1 (2018) Vol 5 No 4 (2017) Vol. 5 No. 4 (2017) Vol. 5 No. 3 (2017) Vol 5 No 3 (2017) Vol 5 No 2 (2017) Vol. 5 No. 2 (2017) Vol 5 No 1 (2017) Vol. 5 No. 1 (2017) Vol. 4 No. 4 (2016) Vol 4 No 4 (2016) Vol. 4 No. 3 (2016) Vol 4 No 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol. 4 No. 1 (2016) Vol 4 No 1 (2016) Vol 3 No 4 (2015) Vol. 3 No. 4 (2015) Vol. 3 No. 3 (2015) Vol 3 No 3 (2015) Vol 3 No 2 (2015) Vol. 3 No. 2 (2015) Vol 3 No 1 (2015) Vol. 3 No. 1 (2015) Vol. 2 No. 4 (2014) Vol 2 No 4 (2014) Vol 2 No 3 (2014) Vol. 2 No. 3 (2014) Vol. 2 No. 2 (2014) Vol 2 No 2 (2014) Vol. 2 No. 1 (2014) Vol 2 No 1 (2014) Vol 1 No 1 (2013) Vol. 1 No. 1 (2013) More Issue